MK

Manish Kumar Sirohi

Active Director Director DIN 11393244
DIN 11393244 First appointment Nov 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Manish Kumar Sirohi

Data last updated:

Manish Kumar Sirohi is a Director at Sbt Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11393244
Primary Designation Director
Industry Pharma
First Appointment 24 Nov 2025

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sbt Pharmaceuticals Private Limited U46497RJ2025PTC107817
Director24 Nov 2025Active

Directorship timeline

Open interactive timeline →
Sbt Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manish Kumar Sirohi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manish Kumar Sirohi

Manish Kumar Sirohi currently holds 1 directorship: Sbt Pharmaceuticals Private Limited (Director, since 24 Nov 2025).

Manish Kumar Sirohi was first appointed on 24 Nov 2025 as Director at Sbt Pharmaceuticals Private Limited.

The current boards of Manish Kumar Sirohi's companies include Amit Kumar Sharma (Sbt Pharmaceuticals Private Limited), Dheeraj Singh (Sbt Pharmaceuticals Private Limited), Rajkumar Choudhary (Sbt Pharmaceuticals Private Limited), Rajveer Singh (Sbt Pharmaceuticals Private Limited), Shashi Lata Choudhary (Sbt Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available